Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors

被引:6
作者
Fukuda, Kazumasa [1 ]
Saikawa, Yoshiro [1 ]
Sako, Hiroyuki [1 ]
Yoshimura, Yumi [1 ]
Takahashi, Tsunehiro [1 ]
Wada, Norihito [1 ]
Kawakubo, Hirohumi [1 ]
Takeuchi, Hiroya [1 ]
Ohmori, Tai [1 ]
Kitagawa, Yuko [1 ]
机构
[1] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan
基金
日本学术振兴会;
关键词
GIST; imatinib; c-KIT; PDGFRA; RECEPTOR TYROSINE KINASE; IMATINIB RESISTANCE; INTERSTITIAL-CELLS; TARGETED THERAPY; PHASE-I; C-KIT; MUTATION; MESYLATE; SURVIVAL; CANCER;
D O I
10.3892/or.2013.2425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
At present, no suitable GIST model exists for the analysis of drug resistance or metastasis using established human gastrointestinal stromal tumor (GIST) cell lines or xenografts even though the molecular mechanisms of drug resistance, progression and metastasis require clarification. The aim of this study was to establish and characterize human GIST cell lines and xenografts that can be used for evaluating drug resistance or various new molecularly targeted therapies. GIST tissues from patients were cultured and implanted under the skin of NOG (NOD/Shi-scid, IL-2Rrnu) mice. Two new cell lines (GK1C and GK3C) and three xenografts (GK1X, GK2X and GK3X) were generated from these clinical samples. The established GIST cell lines and xenografts were investigated for tumorigenesis and imatinib sensitivity. These cell lines and xenografts showed characteristic GIST morphology and exhibited KIT expression profiles similar to those of the patient samples. In addition, these GIST cell lines and xenografts were sensitive to imatinib. In conclusion, new human GIST cell lines and xenografts were established and maintained through repeated passages. These models will enable further study of combination therapies and the mechanisms of resistance, and allow testing of novel targeted monotherapies and combination therapies.
引用
收藏
页码:71 / 78
页数:8
相关论文
共 40 条
[1]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[2]   KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway [J].
Bauer, S. ;
Duensing, A. ;
Demetri, G. D. ;
Fletcher, J. A. .
ONCOGENE, 2007, 26 (54) :7560-7568
[3]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[4]   Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].
Burger, H ;
van Tol, H ;
Boersma, AWM ;
Brok, M ;
Wiemer, EAC ;
Stoler, G ;
Nooter, K .
BLOOD, 2004, 104 (09) :2940-2942
[5]   A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors [J].
Chen, LL ;
Trent, JC ;
Wu, EF ;
Fuller, GN ;
Ramdas, L ;
Zhang, W ;
Raymond, AK ;
Prieto, VG ;
Oyedeji, CO ;
Hunt, KK ;
Pollock, RE ;
Feig, BW ;
Hayes, KJ ;
Choi, H ;
Macapinlac, HA ;
Hittelman, W ;
Velasco, MA ;
Patel, S ;
Burgess, MA ;
Benjamin, RS ;
Frazier, ML .
CANCER RESEARCH, 2004, 64 (17) :5913-5919
[6]   Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group [J].
Debiec-Rychter, M ;
Dumez, H ;
Judson, I ;
Wasag, B ;
Verweij, J ;
Brown, M ;
Dimitrijevic, S ;
Sciot, R ;
Stul, M ;
Vranck, H ;
Scurr, M ;
Hagemeijer, A ;
Van Glabbeke, M ;
van Oosterom, AT .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (05) :689-695
[7]   Clinical management of gastrointestinal stromal tumors: Before and after STI-571 [J].
DeMatteo, RP ;
Heinrich, MC ;
El-Rifai, WM ;
Demetri, G .
HUMAN PATHOLOGY, 2002, 33 (05) :466-477
[8]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[9]   Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy [J].
Eisenberg, BL ;
Judson, I .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (05) :465-475
[10]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2002, 10 (02) :81-89